LY 2109761 is a selective dual TGF-β receptor type I and II (TβRI/II) inhibitor (Ki values are 38 and 300 nM in a cell-free assay, respectively); it inhibits the kinase activity of both TGF-βRI and TGF-βRII.
In vitro
, it significantly inhibits the growth, motility, and invasiveness of L3.6pl/GLT pancreatic cancer cells and completely suppresses TGF-β-induced Smad2 phosphorylation.
In vivo
Caractéristiques techniques
| Marque | Tocris Bioscience |
|---|
| Réf. B-LABO | BL-RE-125677 |
|---|
| Réf. fabricant | 18736075 |
|---|
| Nom chimique ou matériau | 4-[5,6-Dihydro-2-(2-pyridinyl)-4 H-pyrrolo[1,2-b]pyrazol-3-yl]-7-[2-(4-morpholinyl)ethoxy]quinoline |
|---|
| CAS | 700874-71-1 |
|---|
| Quantité | 50 mg |
|---|
| Cible | TGF-beta Receptor Inhibitors |
|---|
| Formule moléculaire | C<sub>26</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub> |
|---|
| Pureté | 0.98 |
|---|
Une question, une configuration particulière ?
Contactez-nous pour un devis.
